Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.

ConditionLymphoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBiogipuzkoa Health Research Institute

About this trial

In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological well-being and quality of life. //2.Reduce fatigue//3.Reduce frailty

There is an association between some biological biomarkers with physical capacity and frailty.

Eligibility criteria

Qualifiers

Age: ≥18 years old.

Diagnosis of lymphoma with histological confirmation and requirement of systemic treatment including chemotherapy.

Time available (80 minutes, two days a week for 20 weeks) to carry out physical exercise sessions.

Have a mobile phone to be able to contact the person and download the physical activity level app.

Disqualifiers

Have a contraindication to moderate-high intensity exercise.

Other significant medical disorders: including psychiatric illnesses chronic or recurrent; intellectual disability, musculoskeletal problems, cardiac or pulmonary disorders that interfere with physical exercise; other malignant tumors in the last five years, with the exception of therapeutically controlled skin cancer; any other illness that may be seen affected or aggravated by physical exercise.

Have plans to be outside city more than two weeks.

People who are already physically active (that comply with the recommendations of WHO: > 150 minutes of exercise moderate/weekly, plus training force two days/week).

Trial design

Treatments tested in this trial

  • Exercise

Treatment groups

180 Participants
are divided into 2 treatment groups